Why the study?
Clinical trials have failed to show a benefit of medical therapy for HFpEF, and medical therapy proven for HFrEF may not address the pathophysiologic basis of HFpEF.
Does transcatheter interatrial shunting improve symptoms and hemodynamics in patients with heart failure with preserved ejection fraction?
Does transcatheter interatrial shunting improve symptoms and hemodynamics in patients with heart failure with preserved ejection fraction?
Transcatheter interatrial shunts represent a novel, potentially safe and effective device-based therapy for HFpEF by unloading the left atrium, though long-term outcomes from ongoing large randomized trials are needed.
Interatrial shunts may relieve HFpEF symptoms short-term; leaves open long-term clinical benefit pending randomized trials.
No takes yet. Share an insight, caveat, or question.
Bhardwaj et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: